Get the Stockscreener App
89.25
1.28%
-1.1694
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $89.25, with a volume of 590.74K.
It is down -1.28% in the last 24 hours and down -5.03% over the past month.
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
See More
Previous Close:
$90.42
Open:
$89.52
24h Volume:
590.74K
Relative Volume:
0.47
Market Cap:
$10.53B
Revenue:
$2.77B
Net Income/Loss:
$286.61M
P/E Ratio:
37.98
EPS:
2.35
Net Cash Flow:
$524.11M
1W Performance:
-0.08%
1M Performance:
-5.03%
6M Performance:
-23.51%
1Y Performance:
-18.30%
1-Day Range:
$88.25
$89.76
1-Week Range:
$88.25
$93.57
52-Week Range:
$88.01
$129.50
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
89.30 | 10.87B | 2.77B | 286.61M | 524.11M | 2.35 |
|
TMO
Thermo Fisher Scientific Inc
|
395.74 | 152.34B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
188.74 | 135.39B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
514.25 | 41.54B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
110.76 | 31.59B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
138.83 | 24.31B | 15.50B | 1.33B | 2.16B | 7.34 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Revvity (RVTY) Introduces New Mimix Standards for Improved IVD Testing | RVTY Stock News - GuruFocus
Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows - Business Wire
Insider Sell: Michelle Mcmurry-heath Sells 600 Shares of Revvity Inc (RVTY) - GuruFocus
Does The Market Have A Low Tolerance For Revvity, Inc.'s (NYSE:RVTY) Mixed Fundamentals? - Yahoo
Shareholders in Revvity (NYSE:RVTY) are in the red if they invested three years ago - simplywall.st
Revvity Inc (RVTY) Shares Up 3.52% on May 27 - GuruFocus
RVTY Stock Falls Despite the Latest Launch of Automated Instrument - MSN
Revvity’s EUROIMMUN unveils new fully automated instrument for specialty testing - SelectScience
Enhancing Laboratory Efficiency with Revvity's IDS i20™ Platform - Lab Manager
Is Wall Street Bullish or Bearish on Revvity Stock? - inkl
Is Wall Street Bullish Or Bearish On Revvity Stock? - Barchart.com
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlo - GuruFocus
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlook | RVTY Stock News - GuruFocus
Sustainable chemistry in India fueling growth with digital and AI innovation: Revvity Signals - Indian Chemical News
Revvity announces launch of new fully automated instrument for specialty testing - BioSpectrum India
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for S - GuruFocus
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing | RVTY Stock News - GuruFocus
Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing - Business Wire
Revvity's New Automated Platform Transforms Specialty Disease Testing with 20-Analyte Capability - Stock Titan
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity Signals Software Inc. v. Cloud Software Group Inc. - Cornerstone Research
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight - GlobeNewswire Inc.
Shareholders Will Be Pleased With The Quality of Revvity's (NYSE:RVTY) Earnings - Yahoo
Revvity at Bank of America 2025 Healthcare Conference: Navigating Tariffs and Growth - Investing.com India
Revvity To Present At Bank Of America Global Healthcare Conference 2025; Webcast At 12:20 PM ET - Nasdaq
Revvity beats quarterly estimates on steady demand for medical equipment - MSN
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know - Yahoo Finance
RVTY Q1 Earnings Call: Resilient Performance Amid Academic and Tariff Headwinds, Software and Diagnostics Shine - Yahoo Finance
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy (NYSE:RVTY) - Seeking Alpha
High Content Screening Market Global Forecasts 2025-2030 - GlobeNewswire
High Content Screening Market Global Forecasts 2025-2030 with Danaher, Revvity, BD, Carl Zeiss, Merck, and Thermo Fisher Scientific Dominating the $2.19 Billion Market - Yahoo Finance
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook - MSN
Revvity Announces Financial Results for the First Quarter of 2025 - ADVFN
UBS Upgrades Revvity (BMV:RVTY) - Nasdaq
UBS Upgrades Revvity (BIT:1RVTY) - Nasdaq
UBS lifts Revvity stock rating to Buy, cuts price target to $115 - Investing.com Australia
UBS Upgrades Revvity (LSE:0KHE) - Nasdaq
UBS Upgrades Revvity (RVTY) - Nasdaq
UBS Boosts Revvity (RVTY) Rating to Buy Amid Growth Prospects | - GuruFocus
UBS lifts Revvity stock rating to Buy, cuts price target to $115 By Investing.com - Investing.com South Africa
UBS Upgrades Revvity to Buy from Neutral, Cuts Price Target to $115 From $145 - marketscreener.com
UBS Boosts Revvity (RVTY) Rating to Buy Amid Growth Prospects | RVTY Stock News - GuruFocus
Revvity to Present at Upcoming Investor Conferences | RVTY Stock News - GuruFocus
KeyBanc Adjusts Revvity's Price Target to $135 From $145 - marketscreener.com
Revvity CEO and CFO to Share Strategic Vision at BofA and Goldman Sachs Healthcare Conferences - Stock Titan
Revvity Reports Strong Q1 2025 Financial Results - TipRanks
Revvity reaffirms 2025 guidance with $4.90-$5 EPS target amid robust software growth - MSN
Stifel maintains Revvity stock Hold rating, $120 target By Investing.com - Investing.com Canada
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):